PTC Therapeutics Insider Sells Shares Amid Product Revenue Growth to $226 Million

Neil Gregory Almstead, Chief Technical Ops Officer at PTC Therapeutics (NASDAQ:PTCT), sold 2,464 shares under a Rule 10b5-1 trading plan. The sale occurred as the company reported product revenue of $226 million and maintained a market cap of $7 billion.

By Jonathan Ponciano, The Motley Fool Tue, July 14, 2026 at 2:48 AM GMT+3 4 min read · Yahoo Finance · July 13, 2026, 23:48 UTC

Tickers: $PTCT

Topics: biopharmaceutical executive sale SEC filing

Read the full article at Yahoo Finance

More World news

Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC